MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE
|Posted date||May 15, 2020|
|International application number||2019JP003802|
|International publication number||WO 2019151514|
|Date of international filing||Feb 4, 2019|
|Date of international publication||Aug 8, 2019|
|Title||MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE|
|Abstract||Provided is a monocyte differentiation inducer which contains albendazole as an active ingredient.|
|Outline of related art and contending technology||
In blood disease, hematopoietic stem cells is inhibited due to the branching processes in the absence of a disease, such as leukemia, aplastic anemia, cost engineer and syndrome.
Leukemia, hematopoietic stem cells (or slightly differentiated cell) to the tumor is considered to be caused by a disease. The chemotherapy treatment is basically in the cure, chemical therapy complications organ toxicity to withstand the general health and organ function needs to be sufficiently maintained because, in older patients often chemotherapy cannot be applied, if there are temporarily no no healing in a patient older not present. For such patients with fewer side effects to the new therapeutic agent is required.
Differentiation as methods of treatment for leukemia with fewer side effects known induction therapy. Differentiation induction therapy, progenitor cells remain at the state of the continued proliferation differentiation leukemia cells, a normal maturation for kill the lifetime of the white original, many anti-cancer chemotherapeutic agent or treatment of leukemia cells such as direct disruption as compared to less side effects. However, an acute promyelocytic leukemia (ATRA) all-trans retinoic acid and/or arsenic is used as a differentiation of neutrophils to the effectiveness of the therapy differentiation induction is established, other leukemia is currently effective differentiation induction therapy is not established. Further, an acute promyelocytic leukemia ATRA of the resistance is present. Leukemia in a wide variety of medical therapies to induce the differentiation of the new effective in strongly demanded.
Aplastic anemia due to some abnormality in the hematopoietic stem cell differentiation and inhibit the disease course, cost man syndrome (alias: severe congenital neutropenia) bone marrow granulocyte-cell maturation and a poor, neutrophils decrease in the group. Leukemia, aplastic anemia, hematopoietic stem cell such as the cost of man syndrome is inhibited due to the branching processes in the disease, decrease in the hematopoietic function, neutrophils and monocytes cell infection is reduced and becomes a problem. As a countermeasure of the bacterial infection in these diseases are, at present, granulocyte-colony stimulating factor (G-CSF) to induce the differentiation of neutrophils such as the agents are administered, G-CSF administration does not increase even after the neutrophils also exist. In order to improve symptoms in these diseases, to promote differentiation of hematopoietic stem cells from the blood to induce the differentiation of valid during the desired agent.
|Scope of claims||
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Contact Information for " MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE "
- Kyoto University Office of Society-Academia Collaboration for Innovation
- URL: https://www.saci.kyoto-u.ac.jp/
- Address: 36-1, Yoshida-honmachi, Sakyo-ku, Kyoto-shi, Kyoto, JAPAN , 606-8501
- Fax: +81-75-753-7591